Federal Court Bans Mailing of Mifepristone Abortion Pill

A federal appeals court blocked the mailing of the prescription abortion drug mifepristone on May 2, 2026, reinstating a requirement that the medication be dispensed in person. The unanimous ruling from the Fifth Circuit Court of Appeals effectively halts a 2023 Food and Drug Administration (FDA) policy that permitted the drug to be prescribed via telehealth and delivered through the mail.

The decision follows arguments from state attorneys who contended that the mailing of the drug bypassed state-level abortion bans. They argued that mifepristone should be restricted to in-person prescriptions or clinic-based dispensing.

“The regulation creates an effective way for an out-of-state prescriber to place the drug in the hands of Louisianans in defiance of Louisiana law”

Circuit Judge Kyle Duncan, Fifth Circuit Court of Appeals

In a rapid response to the ruling, Danco Laboratories, a manufacturer of the medication, petitioned the Supreme Court on May 3, 2026, to reinstate mail access. This legal challenge sets the stage for a potentially significant Supreme Court ruling on abortion access, following the precedent of Dobbs v. Jackson Women’s Health Organization, which eliminated the constitutional right to abortion and returned regulatory authority to individual states.

Impact on Medication Abortion Access

The ruling targets a primary method of abortion access in the post-Roe era. Since the overturning of Roe v. Wade, approximately one in four abortions have been conducted via telehealth appointments. If the Supreme Court upholds the Fifth Circuit’s block, patients may face significantly reduced access to the procedure.

Data from the Guttmacher Institute indicates that medication abortions accounted for 63% of abortions in U.S. States that did not have total bans in 2023. The reliance on this method was even more pronounced in certain rural states, where medication abortions represented 95% of procedures in Wyoming and 84% in Montana.

Mifepristone is part of a two-drug regimen that serves as the most common method for medication abortion. The drug has been FDA-approved since 2000 and the Supreme Court previously dismissed a legal challenge against the medication in 2024. Over the last 20 years, the FDA has consistently addressed safety concerns, citing studies that show the drug is successful in terminating pregnancies 99.6% of the time.

“We are alarmed by this court’s decision to ignore the FDA’s rigorous science and decades of safe use of mifepristone in a case pursued by extremist abortion opponents”

Evan Masingill, CEO of GenBioPro

Legal and Administrative Conflicts

The legal battle over mifepristone reflects a broader conflict between state governments. Following the Dobbs decision, several Democrat-led states implemented shield laws. These laws are designed to protect healthcare providers who prescribe abortion pills via telemedicine and mail them to patients residing in states where abortion is banned.

Louisiana is among several GOP-led states whose attorneys general are attempting to block this access. The Supreme Court’s eventual decision on the mailing ban could significantly impact telehealth restrictions in Missouri, Kansas, and Idaho. Texas and Florida are seeking to ban mifepristone entirely.

Concurrent with these court battles, the Department of Health and Human Services (HHS), under the leadership of Robert F. Kennedy Jr., is reviewing regulations regarding mifepristone. The FDA previously requested that courts pause the current litigation until this administrative review was complete.

While a district court initially granted the FDA’s request to pause the case to prevent immediate changes to drug access, Louisiana appealed that decision. This appeal led the case to the Fifth Circuit Court of Appeals and the subsequent May 2 ruling.

The American Civil Liberties Union has criticized the HHS review, describing the process as a thinly veiled attempt to lay the groundwork for additional medically unjustified restrictions on the medication.